THOMAS JEFFERSON UNIVERSITY HOSPITAL and GenomOncology are co-developing a multi-assay integrated cancer profiling system.
THE EXPERIMENTAL THERAPEUTICS INSTITUTE at the Icahn School of Medicine at Mount Sinai and Regeneron Pharmaceuticals Inc. entered into an agreement with the goal of accelerating the discovery of fully-human antibodies directed against therapeutic targets being researched by Mount Sinai investigators.
SCIEX, a company focused on life science analytical technologies, announced a collaboration with the laboratory of Amanda Paulovich, of Fred Hutchinson Cancer Research Center, to make targeted proteomics in cancer research more reproducible and specific.
HUNTSMAN CANCER INSTITUTE became the first Mediso Preclinical Imaging Center of Excellence in North America.
VANDERBILT-INGRAM CANCER CENTER received an overall “exceptional” score as part of the renewal of the Cancer Center Support Grant.
CHRISTOPH ZIELINSKI was named editor-in-chief of ESMO Open, a new open-access, peer-reviewed online journal published by the European Society of Medical Oncology.
ROBERT SCHREIBER and PHILIP GREENBERG were named editors-in-chief of Cancer Immunology Research, one of eight peer-reviewed journals published by the American Association for Cancer Research.
DAN JONES and ANIL PARWANI were recruited to serve in leadership roles for specialized pathology services offered across The Ohio State University Wexner Medical Center.
MD ANDERSON CANCER CENTER and Esperance Pharmaceuticals Inc. entered into a strategic alliance to accelerate the clinical development of its lead anti-cancer candidate, EP-100, for the treatment of ovarian cancer, and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.
ROBIN DAVISSON was named president and CEO-elect of the Melanoma Research Alliance effective Oct. 1.
